Clinically predictive factors of pathologic upstaging in patients with peripherally located clinical stage IA non-small cell lung cancer

Koji Yamazaki, Ichiro Yoshino, Tomofumi Yohena, Toshifumi Kameyama, Tetsuzo Tagawa, Daigo Kawano, Taro Oba, Hidenori Koso, Yoshihiko Maehara

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)

Abstract

Objective: Post-surgical pathologic examination often reveals a more advanced state than clinically defined in non-small cell lung cancer (NSCLC), posing the need for careful consideration of a lesser resection. We investigated the predictive factors for the pathologic upstaging in clinical stage IA NSCLC. Methods: The clinical features of 253 consecutive patients with peripherally located T1N0M0 NSCLC who underwent complete resection between 1991 and 2004 were investigated in relation to pathologic T- and N-factors. Results: Of the 253 patients, 46 (18.2%) were upstaged after surgery, due to T-factor in 12 patients, N-factor in 32, M-factor in 2 and both T- and N-factors in 1. Among the clinical parameters, a higher level of serum CEA (p = 0.0378) and larger tumor size (p = 0.0276) were observed in the upstaged patients. Multivariable analysis revealed that tumor size and positive serum CEA were independently associated with pathologic upstaging. When tumor size was greater than 10 mm, patients with positive serum CEA (>2.0 ng/ml) showed a significantly higher incidence of pathologic upstaging (29.2%) than the rest (15.5%, p = 0.0461). Conclusion: Clinically defined peripheral stage IA NSCLC should be carefully indicated for a lesser resection when positive serum CEA and/or tumors greater than 10 mm in size are observed.

Original languageEnglish
Pages (from-to)365-369
Number of pages5
JournalLung Cancer
Volume55
Issue number3
DOIs
Publication statusPublished - Mar 2007

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint

Dive into the research topics of 'Clinically predictive factors of pathologic upstaging in patients with peripherally located clinical stage IA non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this